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n-Butyrate was previously found to increase the epidermal growth factor (EGF) receptor binding in primary cultures 
of rat hepatocytes. We show here that butyrate and dexamethasone synergistically modulate the surface expression of 
the EGF receptors. The butyrate-induced nhancement of high-affinity EGF binding was only slight in the absence of 
glucocorticoid, but was strongly and dose-dependently amplified by dexamethasone. Butyrate counteracted the inhibition 
by insulin of the dexamethasone-induced increase in EGF binding. The results indicate that the glucocorticoid has a 
permissive effect on a butyrate-sensitive process that determines the surface xpression of the high-affinity class of EGF 
receptors. 
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1. INTRODUCTION 
Epidermal growth factor (EGF) is a strong 
mitogen [1] that acts through specific transmem- 
brane receptors [2]. In many cells the surface ex- 
pression of EGF receptors has been found to be 
related to the state of cell differentiation [3-5]. 
The number of EGF receptors can be increased by 
agents capable of inducing morphological dif- 
ferentiation i  cultured cells, such as cAMP [6] 
and retinoids [3,7], and also by glucocorticoids [8]. 
n-Butyrate has profound effects on many cultured 
cells. This agent may preserve an apparently dif- 
ferentiated morphology, inhibit growth and cause 
selective alterations in gene expression [9]. We 
have recently reported that butyrate up-regulates 
EGF receptors in primary cultures of rat 
hepatocytes [10]. In particular, butyrate preserved 
the high-affinity receptor subpopulation [10] 
which is present on freshly isolated hepatocytes 
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[11]. Since glucocorticoids have also been shown to 
increase EGF binding in hepatocytes [12], and dex- 
amethasone was routinely present in the medium in 
[10], it was of interest to examine the relationship 
between the glucocorticoid-induced and the 
butyrate-induced ffects on EGF receptors. We 
report here that the two agents act synergistically, 
dexamethasone exerting a strong permissive ffect 
on the ability of butyrate to enhance the surface 
expression of EGF receptors in cultured 
hepatocytes. 
2. MATERIALS AND METHODS 
2.1. Materials 
~251-EGF (spec. act. 105-132 Ci/g) was from Amersham In- 
ternational (Buckinghamshire, England). Unlabeled EGF 
(receptor grade) was from Collaborative Research, Inc. (Bed- 
ford, MA). Sodium n-butyrate, dexamethasone, bovine serum 
albumin (fraction V) and collagen (rat tail, type VII) were from 
Sigma (St. Louis, MO). Insulin was from Novo (Copenhagen, 
Denmark). 
2.2. Hepatocyte isolation and culture 
Male Wistar rats (180-220g) were fed ad libitum. 
Hepatocytes were isolated as described [11] and seeded into 
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Costar plastic culture wells (12-well dishes) with collagen in a 
1 : 100 dilution [l 3] at cell densities of 25000 cells/cm 2.The cells 
were cultured without serum in a 1 : 1 combination of Dulbec- 
co's modified Eagle's medium with low glucose (5.6 mM) and 
Waymouth's medium MAB 87/3 (Gibco, Grand Island, NY) 
modified as described [14], supplemented with penicillin 
(67 #g/ml) and streptomycin (100 #g/ml). The medium was not 
changed during the culture period, n-Butyrate and dex- 
amethasone at the indicated concentrations were added 2-3 h 
after plating. Insulin (100 nM) was added at the time of plating. 
2.3. 125I-EGF binding assays 
The monolayers were washed twice with ice-cold Krebs- 
Hepes-Ringer buffer with 1 o7o bovine albumin, pH 7.4 (binding 
buffer). For estimation of surface binding the cells were chilled 
on ice for 30 min, and incubated with 1251-EGF in binding buf- 
fer to a total volume of 0.6 ml per well at 0°C for 20 h. For 
saturation binding analysis labeled EGF was diluted with 
unlabeled EGF in a fixed ratio of 1:9 as described [11]. After 
removing the medium and rinsing the monolayers four times the 
cells were dissolved in 0.5 N NaOH for 2 h at room 
temperature. The radioactivity in the medium (free ligand) and 
in the dissolved cells (bound ligand) was measured separately in
a gamma counter. The nonspecific binding was estimated by 
measuring the binding in the presence of 300 nM unlabeled 
EGF. Protein was determined according to Lowry et al. [15]. 
EGF binding activity was expressed as fmol EGF/mg cell pro- 
tein. Data for Scatchard analysis were analyzed by the 
LIGAND computer program [16], and the best fit of the data 
to a one-site or a two-site model was evaluated by the F statistics 
test incorporated in the program. 
3. RESULTS 
The  decl ine o f  EGF  b ind ing in hepatocytes  oc- 
cur r ing  dur ing culture [12] can be restored by 
butyrate  [10]. Fig. 1 shows the ef fect  o f  butyrate  on 
the h igh-a f f in i ty  EGF  b inding in the absence or  
presence o f  250 nM dexamethasone .  The EGF  
b ind ing  was determined at a low l igand concentra -  
t ion  (20 pM labeled EGF)  to permit  b ind ing 
predominant ly  to the h igh-af f in i ty  receptor  class 
[10]. In the absence o f  the g lucocor t ico id ,  butyrate  
had on ly  a sl ight and inconstant  ef fect  on  the EGF  
b ind ing.  In the presence o f  dexamethasone ,  
however ,  butyrate  dose-dependent ly  (1 -5  mM)  in- 
creased the EGF  b inding (fig. 1A). In addi t ion,  the 
dose-dependent  increase o f  EGF  b ind ing caused by 
dexamethasone  [12] was also marked ly  potent ia ted  
by 5 mM butyrate  ( f ig.2A).  Insul in (100 nM)  in- 
h ib i ted the dexamethasone- induced  increase in 
EGF  b ind ing (f ig.2) as descr ibed [12]. Insul in also 
s l ight ly depressed the EGF  receptor  b ind ing in 
butyrate - t reated cells (figs 1,2). It should be noted,  
however ,  that  butyrate  to a large extent abol ished 
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Fig.1. Dose-dependent effects of butyrate on the high-affinity 
EGF receptor binding in the absence and presence of 
dexamethasone. Rat hepatocytes were cultured in medium 
without insulin (A) or with 100 nM insulin (B). Dexamethasone 
(250 nM) and varying concentrations of butyrate were added 
2 h after plating when indicated. After 42 h in culture the cells 
were incubated at 0°C for 20 h with 20 pM labeled EGF. Each 
point represents he mean _+ SE of three cultures. 
the inh ib i t ion by insul in [12] o f  the 
dexamethasone- induced  receptor  up- regu lat ion  
( f ig .2a) .  
Scatchard  analysis o f  the EGF  b ind ing to cells 
cu l tured  in the presence o f  insul in (100 nM)  
( f ig .3A) or  insul in (100 nM)  plus dexamethasone  
(250 nM)  (f ig.3B) revealed l inear b ind ing plots,  
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Fig.2. Dose-dependent effects of dexamethasone on EGF 
receptor binding in the absence and presence of butyrate. 
Hepatocytes were cultured in medium without insulin (A) or 
with 100 nM insulin (B). Butyrate (5 mM) and varying 
concentrations of dexamethasone w re added 3 h after plating 
as indicated. EGF binding was determined after 42 h in culture, 
using 20 pM labeled EGF. Each point represents he mean _+ SE 
of six cultures from two experiments. 
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Fig.3. Scatchard analysis of EGF binding. Hepatocytes were 
cultured in medium supplemented with 100 nM insulin (A) or 
100 nM insulin + 250 nM dexamethasone (B).Butyrate (5 raM) 
was added 3 h after plating of the cells as indicated. After 42 h 
in culture, the cells were assayed for EGF binding as described 
in section 2. Each point represents the mean of two cultures. 
One of three experiments. 
suggesting the presence of a single binding activity 
in these cells. When 5 mM butyrate was added 
2-3  h after plating, curvilinear binding plots sug- 
gesting the presence of different affinity states of 
the receptor emerged in hepatocytes treated with 
dexamethasone and insulin, but not if dexametha- 
sone was excluded. Computer (LIGAND) analysis 
of data from three independent experiments on 
cells exposed to butyrate in the presence of dexa- 
methasone and insulin showed that a two-site 
model was a better fit than a one-site model (P = 
0.008), with a high-affinity receptor population 
with Kd = 0.011 nM comprising about 4°7o of the 
total receptors, and a low-affinity population with 
Kd = 0.37 nM. In cells cultured with insulin in the 
absence of dexamethasone, butyrate did not affect 
the affinity of EGF for its receptor, the Kd being 
0.99 nM and 0.98 nM in the absence and presence 
of butyrate, respectively. Addition of dexametha- 
sone to insulin-treated cells in the absence of 
butyrate very slightly increased the affinity (from 
Kd = 0.99 nM to Kd = 0.54 nM). 
4. DISCUSSION 
As a growth factor receptor tyrosine kinase 
showing homology with the erbB-1 oncogene 
product, the EGF receptor has been widely ap- 
preciated to play an important role in cell pro- 
liferation [1,2]. Changes in the EGF receptor 
status, which can occur through transcriptional 
control [17], receptor internalization/externaliza- 
tion [18], or changes in affinity [19], may confer 
upon the cell new patterns of growth respon- 
siveness. In liver, several reports have focused on 
the regulation of the EGF receptor. The receptor 
number decli.nes both in regenerating liver after 
partial hepatectomy [20] and in hepatocytes plated 
in primary culture [12]. Lin et al., who studied hor- 
monal modulation of EGF binding to hepatocytes 
in primary culture, showed that glucocorticoids in- 
crease the EGF binding and that this increase is in- 
hibited by insulin [12]. We have recently found 
that n-butyrate enhances the EGF binding in 
cultured hepatocytes [10]. The present report 
demonstrates that there is a marked synergism be- 
tween the glucocorticoid dexamethasone and 
butyrate in the up-regulation of surface EGF 
receptors, particularly the high-affinity binding, in 
cultured hepatocytes. Dexamethasone was re- 
quired for the effect of butyrate, and butyrate in- 
creased the effect of dexamethasone and 
counteracted the inhibition by insulin on the 
dexamethasone-induced up-regulation of the EGF 
receptors. 
The molecular mechanisms responsible for the 
observed interaction between dexamethasone and 
butyrate are not known. Both dexamethasone and 
butyrate have been found to inhibit hepatocyte 
DNA synthesis [10,21] and promote differentiated 
characteristics in primary hepatocyte culture 
[21,22]. Butyrate affects a large number of nuclear 
processes and causes histone hyperacetylation, but 
the precise mechanisms responsible for the effects 
of butyrate have not been resolved. Certain obser- 
vations may suggest an interaction between the ef- 
fects of butyrate and those of glucocorticoids at 
the level of gene transcription. Both butyrate and 
dexamethasone induce the metallothionein-I gene 
in hepatoma ceils [23] and increase the number of 
fl-adrenoceptors in the 3T3-L1 preadipocyte 
system [24]. Butyrate also increases the capacity of 
dexamethasone to induce the alkaline phosphatase 
activity of HeLa $3 cells [25] but inhibits the ex- 
pression of certain glucocorticoid-inducible g ne 
products in HTC cells [26]. Taken together, these 
reports may suggest converging effects of 
glucocorticoids and butyrate at the level of gene 
transcription. The present results indicate that in 
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helaatocytes butyra te  and dexamethasone  syner-  
gist ical ly af fect  the EGF  receptor  status, part ic-  
u lar ly  increasing the h igh-af f in i ty  receptor  sub- 
popu la t ion .  A l though it is conce ivab le  that  
butyrate  af fects  t ranscr ipt ion  o f  the EGF  receptor  
gene,  it is also possible that  it acts th rough a 
t ranscr ip t ion -dependent  process that  indirect ly 
mcDb~a~ es "~n e~__~VJS ~ IeCgI)'tDI ,DrqI)el'f~es. uc'~ as't'ne 
aggregat ion  state [19] or  phosphory la t ion  [2,27], 
which  may alter receptor  af f in i ty.  
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